These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

346 related articles for article (PubMed ID: 38988204)

  • 1. Neutralization of SARS-CoV-2 Omicron XBB.1.5 and JN.1 variants after COVID-19 booster-vaccination and infection.
    Springer DN; Camp JV; Aberle SW; Deutsch J; Lammel O; Weseslindtner L; Stiasny K; Aberle JH
    J Med Virol; 2024 Jul; 96(7):e29801. PubMed ID: 38988204
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhancing Omicron Sublineage Neutralization: Insights From Bivalent and Monovalent COVID-19 Booster Vaccines and Recent SARS-CoV-2 Omicron Variant Infections.
    Jeong HW; Rollon R; Kim SM; Gil J; Casel MA; Jang H; Choi JH; Jang SG; Lazarte JC; Kim HS; Kim JH; Choi YK
    Influenza Other Respir Viruses; 2024 Oct; 18(10):e70000. PubMed ID: 39377176
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Distinct patterns of SARS-CoV-2 BA.2.87.1 and JN.1 variants in immune evasion, antigenicity, and cell-cell fusion.
    Li P; Liu Y; Faraone JN; Hsu CC; Chamblee M; Zheng Y-M; Carlin C; Bednash JS; Horowitz JC; Mallampalli RK; Saif LJ; Oltz EM; Jones D; Li J; Gumina RJ; Liu S-L
    mBio; 2024 May; 15(5):e0075124. PubMed ID: 38591890
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neutralizing antibody response to XBB.1.5, BA.2.86, FL.1.5.1, and JN.1 six months after the BNT162b2 bivalent booster.
    Favresse J; Gillot C; Cabo J; David C; Dogné JM; Douxfils J
    Int J Infect Dis; 2024 Jun; 143():107028. PubMed ID: 38583825
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Finite immune imprinting on neutralizing antibody responses to Omicron subvariants by repeated vaccinations.
    Song XD; Yang GJ; Shi C; Jiang XL; Wang XJ; Zhang YW; Wu J; Zhao LX; Wang MM; Chen RR; He XJ; Dai EH; Shen Y; Gao HX; Dong G; Ma MJ
    Int J Infect Dis; 2024 Oct; 147():107198. PubMed ID: 39117174
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Robust SARS-CoV-2-neutralizing antibodies sustained through 6 months post XBB.1.5 mRNA vaccine booster.
    Wang Q; Mellis IA; Guo Y; Gherasim C; Valdez R; Gordon A; Ho DD; Liu L
    Cell Rep Med; 2024 Sep; 5(9):101701. PubMed ID: 39208800
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interim Report of the Reactogenicity and Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 XBB-Containing Vaccines.
    Chalkias S; McGhee N; Whatley JL; Essink B; Brosz A; Tomassini JE; Girard B; Edwards DK; Wu K; Nasir A; Lee D; Avena LE; Feng J; Deng W; Montefiori DC; Baden LR; Miller JM; Das R
    J Infect Dis; 2024 Aug; 230(2):e279-e286. PubMed ID: 38349280
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SARS-CoV-2 BA.4/5 infection triggers more cross-reactive FcγRIIIa signaling and neutralization than BA.1, in the context of hybrid immunity.
    Richardson SI; Mzindle N; Motlou T; Manamela NP; van der Mescht MA; Lambson BE; Everatt J; Amoako DG; Balla S; von Gottberg A; Wolter N; de Beer Z; de Villiers TR; Bodenstein A; van den Berg G; Abdullah F; Rossouw TM; Boswell MT; Ueckermann V; Bhiman JN; Moore PL
    J Virol; 2024 Jul; 98(7):e0067824. PubMed ID: 38953380
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative immunogenicity of monovalent and bivalent adenovirus vaccines carrying spikes of early and late SARS-CoV-2 variants.
    Li H; Yang C; Yin L; Liu W; Zhang Z; Liu B; Sun X; Liu W; Lin Z; Liu Z; He P; Feng Y; Wang C; Wang W; Guan S; Wang Q; Chen L; Li P
    Emerg Microbes Infect; 2024 Dec; 13(1):2387447. PubMed ID: 39082740
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Original COVID-19 priming regimen impacts the immunogenicity of bivalent BA.1 and BA.5 boosters.
    Zaeck LM; Tan NH; Rietdijk WJR; Geers D; Sablerolles RSG; Bogers S; van Dijk LLA; Gommers L; van Leeuwen LPM; Rugebregt S; Goorhuis A; Postma DF; Visser LG; Dalm VASH; Lafeber M; Kootstra NA; Huckriede ALW; Haagmans BL; van Baarle D; Koopmans MPG; ; van der Kuy PHM; GeurtsvanKessel CH; de Vries RD
    Nat Commun; 2024 May; 15(1):4224. PubMed ID: 38762522
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relative vaccine protection, disease severity, and symptoms associated with the SARS-CoV-2 omicron subvariant BA.2.86 and descendant JN.1 in Denmark: a nationwide observational study.
    Moustsen-Helms IR; Bager P; Larsen TG; Møller FT; Vestergaard LS; Rasmussen M; Hansen CH;
    Lancet Infect Dis; 2024 Sep; 24(9):964-973. PubMed ID: 38761806
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low neutralization of SARS-CoV-2 Omicron BA.5.2.48 and XBB.1 sub-variants in response to breakthrough infection by booster.
    Li J; Gong L; Li J; Gong Z; Wang X; Yan H; Zhang Y; Mao H; Chen K
    Vaccine; 2024 Jul; 42(18):3751-3755. PubMed ID: 38714449
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diversified humoral immunity and impacts of booster vaccines: SARS-CoV-2 antibody profile and Omicron BA.2 neutralization before and after first or second boosters.
    Zhang XS; Windau A; Meyers J; Yang X; Dong F
    Microbiol Spectr; 2024 Oct; 12(10):e0060524. PubMed ID: 39162540
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neutralization of EG.5, EG.5.1, BA.2.86, and JN.1 by antisera from dimeric receptor-binding domain subunit vaccines and 41 human monoclonal antibodies.
    He Q; An Y; Zhou X; Xie H; Tao L; Li D; Zheng A; Li L; Xu Z; Yu S; Wang R; Hu H; Liu K; Wang Q; Dai L; Xu K; Gao GF
    Med; 2024 May; 5(5):401-413.e4. PubMed ID: 38574739
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epidemiological characteristics and antibody kinetics of elderly population with booster vaccination following both Omicron BA.5 and XBB waves in China.
    Zhao XJ; Liu XL; Liang YM; Zhang S; Liu T; Li LB; Jiang WG; Chen JJ; Xu Q; Lv CL; Jiang BG; Kou ZQ; Wang GL; Fang LQ
    J Med Virol; 2024 May; 96(5):e29640. PubMed ID: 38699969
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neutralizing antibody responses and cellular responses against SARS-CoV-2 Omicron subvariants after mRNA SARS-CoV-2 vaccination in kidney transplant recipients.
    Kawashiro K; Suzuki R; Nogimori T; Tsujino S; Iwahara N; Hirose T; Okada K; Yamamoto T; Fukuhara T; Hotta K; Shinohara N
    Sci Rep; 2024 May; 14(1):12176. PubMed ID: 38806644
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of cross-neutralizing immunity following COVID-19 primary series vaccination during the Omicron surge in Tanzania.
    Nkinda L; Barabona G; Ngare I; Nkuwi E; Kamori D; Msafiri F; Kunambi PP; Osati E; Kidenya BR; Chuwa H; Kinasa G; Hassan FE; Judicate GP; Gasper J; Kisuse J; Mfinanga S; Senkoro M; Ueno T; Lyamuya E; Balandya E
    J Med Virol; 2024 Aug; 96(8):e29822. PubMed ID: 39056238
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Repeated Omicron infection dampens immune imprinting from previous vaccination and induces broad neutralizing antibodies against Omicron sub-variants.
    Gong X; Peng L; Wang F; Liu J; Tang Y; Peng Y; Niu S; Yin J; Guo L; Lu H; Liu Y; Yang Y
    J Infect; 2024 Aug; 89(2):106208. PubMed ID: 38908522
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vaccination and Omicron BA.1/BA.2 Convalescence Enhance Systemic but Not Mucosal Immunity against BA.4/5.
    Diem G; Jäger M; Dichtl S; Bauer A; Lass-Flörl C; Reindl M; Wilflingseder D; Posch W
    Microbiol Spectr; 2023 Jun; 11(3):e0516322. PubMed ID: 37098903
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Humoral response superiority of the monovalent XBB.1.5 over the bivalent BA.1 and BA.5 mRNA COVID-19 vaccines.
    Lustig Y; Barda N; Weiss-Ottolenghi Y; Indenbaum V; Margalit I; Asraf K; Doolman R; Chalkias S; Das R; Elfatarany G; Harats D; Kreiss Y; Regev-Yochay G
    Vaccine; 2024 Sep; 42(22):126010. PubMed ID: 38806352
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.